Gly­coMimet­ics stock rock­ets up on the lat­est ‘break­through’ ti­tle in can­cer R&D

Late last year Rockville, MD-based Gly­coMimet­ics turned up at ASH to re­port out an ear­ly snap­shot of some pos­i­tive out­comes from the first stage of a Phase I/II study of GMI-1271, its E-se­lectin an­tag­o­nist, for a small group of pa­tients with acute myeloid leukemia. And with an­oth­er batch of da­ta be­ing read­ied for AS­CO in a cou­ple of weeks, the biotech says that the FDA has help­ful­ly pro­vid­ed a break­through drug des­ig­na­tion to help them ac­cel­er­ate the de­vel­op­ment work through to a po­ten­tial mar­ket­ing ap­pli­ca­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.